Compensated Awareness Post View
Disclaimer
Medicure Inc. (MCUJF) Fights the High Risks Associated with Common Heart Disease
Coronary heart disease is the most common killer United States and Europe. Acute coronary syndrome (ACS), a common complication of coronary heart disease, is associated with more than 2.5 million hospitalizations worldwide each year. Medicure Inc. is a specialty pharmaceutical company that directs its attention in areas that fight back these staggering numbers through its research, clinical development and commercialization of human therapeutics.
The company has raised over $140 million and has allocated it toward the clinical development of cardiovascular drugs. In 2006 Medicure acquired the USA commercial rights to the cardiovascular drug, AGGRASTAT (tirofiban HCl), originally developed by Merck. AGGRASTAT (an antiplatelet medicine that prevents blood clots from forming), along with Heparin, is indicated for the treatment of acute coronary syndrome. Medicure’s builds value for its shareholders by generating revenue to support operations and make investments in the drug’s clinical advancement.
The company’s central focus is on the US commercial sales of FDA-approved small molecule, AGGRASTAT, and leverages the company’s experienced commercial team to facilitate bringing it to market. As of late, there is renewed interest in the drug coming from hospitals and clinicians as a result of notable clinical and economic data. Furthermore, Aggrastat is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
The US rights to Aggrastat are owned by Medicure’s subsidiary, Medicure International, Inc. (Barbados) and the product is distributed in the United States by Medicure’s US subsidiary, Medicure Pharma, Inc. The company sees small molecule development opportunities as one would conclude from MCUJF’s current development programs in the neurology and cardiology fields.
For more information on the company visit www.medicure.com
